SCHEMBL7056947

SCHEMBL7056947

CCOC(=O)C[C@H](O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 2/20 0.50
MMP8 P22894 1/20 0.49
F2 P00734 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
F10 P00742 1/20 0.45
PIN1 Q13526 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL295741 1.00 ALDH1A1 (0.53) ALDH1A1TSHRLMNAKDM4EMMP8
SCHEMBL10391474 1.00 ALDH1A1 (0.53) ALDH1A1TSHRLMNAKDM4EMMP8
SCHEMBL6544635 0.87 ALDH1A1 (0.48) ALDH1A1TSHRLMNAKDM4EMMP8
SCHEMBL7178642 0.85 ALDH1A1 (0.55) ALDH1A1TSHRLMNAMMP8F2
SCHEMBL4497421 0.84 KMT2A (0.49) ALDH1A1TSHRLMNAKDM4EKMT2A
SCHEMBL4497426 0.84 KMT2A (0.49) ALDH1A1TSHRLMNAKDM4EKMT2A
SCHEMBL232194 0.84 F2 (0.59) ALDH1A1TSHRMMP8F2MEN1
SCHEMBL27461469 0.83 SMN1; SMN2 (0.58) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL5929625 0.83 NAMPT (0.42) ALDH1A1TSHRLMNAKDM4EKMT2A
SCHEMBL6505602 0.83 ALDH1A1 (0.49) ALDH1A1TSHRLMNAKDM4EMMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118513079-A Polymer-coated mesoporous silica supported ruthenium catalyst and preparation method and application thereof 浙江工业大学 2024-08-20 CN disclosed
WO-2022235866-A1 COVALENT RAS INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-11-10 WO disclosed
US-10668090-B2 Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof ZHEJIANG PALO ALTO PHARMACEUTICALS, INC (CN) 2020-06-02 US disclosed
US-20190125771-A1 LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) 2019-05-02 US disclosed
EP-3476854-A1 LIVER DELIVERY-BASED ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF Zhejiang Paloalto Pharmaceutical Technology Co Ltd (CN) 2019-05-01 EP disclosed
CN-106366980-A Corrosion-resistant anaerobic adhesive 无锡万能胶粘剂有限公司 2017-02-01 CN disclosed
CN-102796068-A Method for synthetizing (R)-(plus)-pinocembrin and (S)-(minus)-pinocembrin INST MATERIA MEDICA CAMS 2012-11-28 CN disclosed
CN-101230319-B Saccharomyces cerevisiae CGMCC No.2266 and its application in preparation of (S)-(-)- beta-hydroxyphenyl propionic acid ethyl UNIV ZHEJIANG TECHNOLOGY 2010-06-02 CN disclosed
CN-101230319-A Saccharomyces cerevisiae CGMCC No.2266 and its application in preparation of (S)-(-)- beta-hydroxyphenyl propionic acid ethyl UNIV ZHEJIANG TECHNOLOGY (CN) 2008-07-30 CN disclosed
CN-1768046-A Amine-substituted diphenyldiphosphines and its application in asymmetric synthetic metal complex SOLVIAS AG (CH) 2006-05-03 CN disclosed
EP-0941231-B1 Heteroarylic-arylic diphosphines as chiral ligands CHEMI SPA (IT) 2003-05-02 EP disclosed
US-6153758-A Heteroarylic-arylic diphosphines as chiral ligands CHEMI S.P.A. (IT) 2000-11-28 US disclosed
EP-0941231-A1 HETEROARYLIC-ARYLIC DIPHOSPHINES AS CHIRAL LIGANDS CHEMI S.p.A. (IT) 1999-09-15 EP disclosed
WO-1998022484-A1 HETEROARYLIC-ARYLIC DIPHOSPHINES AS CHIRAL LIGANDS CHEMI S.P.A. (IT) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125771-A1 LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF SLC10A1, NPC1, NPC1L1 ALDH1A1 2965/4885TSHR 4759/4885LMNA 2438/4885
US-10668090-B2 Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof SLC10A1, NPC1, NPC1L1 ALDH1A1 2965/4885TSHR 4759/4885LMNA 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.